Figure 2D shows a remarkably significant increase in UCP2 protein expression levels when cells were treated with SeMet at both concentrations (+42% for 10 nM and +113% for 10 μM), in addition to a decrease in UCP2 protein levels when cells were treated with SeCys at 10 μM (−24%). Western blot cropped representative bands of selenomethione-treated and selenocystine-treated MCF-7 breast cancer cells can be observed in Figure 3. Here, UCP2 is linked to breast carcinoma.